Latest Breaking News On - Global asthma network - Page 12 : comparemela.com

  an anti-inflammatory reliever in mild asthma   therapy approved in China for mild, moderate and severe asthma   AstraZeneca s Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older.   The approval by the National Medical Products Administration (NMPA) was based on positive results from the SYGMA 1 and SYGMA 2 Phase III trials, published in TheNew England Journal of Medicine, which evaluated the efficacy of Symbicort Turbuhaler taken as-needed as an anti-inflammatory reliever compared with standard of care (SoC) therapies in mild asthma. SoC included short-acting beta2-agonist (SABA) taken as-needed or regular maintenance controller therapy (twice-daily budesonide, an inhaled corticosteroid (ICS)) plus SABA taken as-needed.

United kingdomUnited statesSymbicort turbuhalerBuhlr budesonideAstrazeneca symbicort turbuhalerAdrian kempAstrazeneca pharmaceuticalsChinese thoracic societyInternational study groupCompany on twitter astrazenecaChina thoracic societyInvestor relations teamNational asthma guidelinesNational medical products administrationGlobal asthma networkBlood institute